M&A Deal Summary

Takeda Acquires Baxalta - Biologics Manufacturing Facility

On January 5, 2016, Takeda acquired life science company Baxalta - Biologics Manufacturing Facility from Baxalta

Acquisition Highlights
  • This is Takeda’s 8th transaction in the Life Science sector.
  • This is Takeda’s 7th transaction in the United States.
  • This is Takeda’s 1st transaction in Minnesota.

M&A Deal Summary
Date 2016-01-05
Target Baxalta - Biologics Manufacturing Facility
Sector Life Science
Buyer(s) Takeda
Sellers(s) Baxalta
Deal Type Divestiture

Target

Baxalta - Biologics Manufacturing Facility

Brooklyn Park, Minnesota, United States
Baxalta - Biologics Manufacturing Facility is a producer of Entyvio® (vedolizumab) and other biologic products.

Search 198,485 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Takeda

Tokyo, Japan
Category Company
Founded 1781
Sector Life Science
Employees47,347
Revenue 4.03T JPY (2023)
DESCRIPTION
Takeda's corporate headquarters in Tokyo, Japan.
Takeda's corporate headquarters in Tokyo, Japan.

Takeda is a global biopharmaceutical organization committed to improving the health and well-being of people worldwide. Takeda is dedicated to addressing unmet medical needs through the development of innovative and transformative therapies. The Company's diverse portfolio encompasses a wide range of therapeutic areas, including oncology, gastroenterology, rare diseases, neuroscience, and vaccines. Takeda was originally established in 1781 and is based in Tokyo, Japan.

DEAL STATS #
Overall 9 of 18
Sector (Life Science) 8 of 17
Type (Divestiture) 1 of 3
State (Minnesota) 1 of 1
Country (United States) 7 of 12
Year (2016) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-12-16 Takeda Pharmaceutical Company - Core Respiratory Business

Japan

Takeda Pharmaceutical Company Limited's core respiratory business includes the expansion of rights to roflumilast (marketed as Daliresp in the US and Daxas in other countries), the only approved oral PDE4 inhibitor for the treatment of chronic obstructive pulmonary disease (COPD).

Sell $575M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2017-01-09 Ariad Pharmaceuticals

Cambridge, Massachusetts, United States

Ariad Pharmaceuticals, Inc. is an oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines.

Buy $5.2B

Seller(S) 1

SELLER

Baxalta

Deerfield, Illinois, United States
Category Company
Founded 2014
Sector Life Science
Employees16,000
DESCRIPTION
Entrance to Baxalta office in Milford, Massachusetts.
Entrance to Baxalta office in Milford, Massachusetts.

Baxalta Incorporated is a global biopharmaceutical company developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, oncology and immunology.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (Minnesota) 1 of 1
Country (United States) 1 of 1
Year (2016) 1 of 1
Mergr

Product

Company

Legal